Large Amounts of Vascular Endothelial Growth Factor at the Site of Hemostatic Plug Formation In Vivo
- 1 July 1999
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (7) , 1757-1760
- https://doi.org/10.1161/01.atv.19.7.1757
Abstract
Abstract —Vascular endothelial growth factor (VEGF) is important for the proliferation, differentiation, and survival of microvascular endothelial cells. It is a potent angiogenic factor and a specific endothelial cell mitogen that increases fenestration and extravasation of plasma macromolecules. Recently, large quantities of VEGF were detected in human megakaryocytes. Incubation of human platelets with thrombin in vitro resulted in the release of large amounts of VEGF. To investigate whether VEGF is released from platelets during coagulation activation in vivo, we measured in human subjects VEGF at the site of plug formation, ie, in blood emerging from a standardized injury made to determine bleeding time (shed blood). VEGF was also determined in the same volunteers after treatment with the specific thrombin inhibitor recombinant hirudin (r-hirudin). In a double-blind, randomized, crossover study, 17 healthy male volunteers (aged 20 to 35 years) were investigated. VEGF concentrations were measured in venous blood and in shed blood by the use of an immunoassay 10 minutes after intravenous administration of r-hirudin (0.35 mg/kg of body weight) or physiological saline. Prothrombin fragment f1.2 (f1.2) and β-thromboglobulin (β-TG) were determined as indicators of coagulation and platelet activation, respectively. Concentrations of VEGF, f1.2, and β-TG in shed blood 4 minutes after injury were significantly higher than in venous blood (VEGF, 55.8±9.2 versus P P P 50% inhibition of the β-TG and f1.2 levels in shed blood. In a similar manner, much lower amounts of VEGF were detectable at the site of plug formation after r-hirudin treatment (69.0±9.5 versus 37.8±2.6 pg/mL per minute; P =0.0015). Our data indicate that substantial quantities of VEGF are released from platelets during the interaction with the injured vessel wall in vivo. This finding may be relevant with respect to wound healing and tissue repair, tumor vascularization, or arterial thrombus formation.Keywords
This publication has 20 references indexed in Scilit:
- Prevention of Venous Thromboembolism in Cancer Using Low-Molecular-Weight HeparinsPathophysiology of Haemostasis and Thrombosis, 1997
- Vascular endothelial growth factorEuropean Journal Of Cancer, 1996
- The Regulation of Blood Vessel Growth by Vascular Endothelial Growth FactorAnnals of the New York Academy of Sciences, 1995
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: An Important Mediator of Angiogenesis in Malignancy and InflammationInternational Archives of Allergy and Immunology, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature, 1992
- Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosisThe Lancet, 1992
- Vascular permeability factor: A unique regulator of blood vessel functionJournal of Cellular Biochemistry, 1991
- Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis.Journal of Clinical Investigation, 1989
- THROMBOXANE A2 IN SKIN-BLEEDING-TIME BLOOD AND IN CLOTTED VENOUS BLOOD BEFORE AND AFTER ADMINISTRATION OF ACETYLSALICYLIC ACIDThe Lancet, 1983